Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy IsoPlexis stock

Learn how to easily invest in IsoPlexis stock.

IsoPlexis Corp is a medical devices business based in the US. IsoPlexis shares (ISO) are listed on the NASDAQ and all prices are listed in US Dollars. IsoPlexis employs 459 staff and has a trailing 12-month revenue of around $18.7 million.

How to buy shares in IsoPlexis

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ISO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

IsoPlexis stock price (NASDAQ: ISO)

Use our graph to track the performance of ISO stocks over time.

IsoPlexis shares at a glance

Information last updated 2022-09-23.
Latest market close$1.75
52-week range$1.62 - $16.95
50-day moving average $2.47
200-day moving average $3.93
Wall St. target price$3.83
PE ratio 0.1786
Dividend yield $0 (0%)
Earnings per share (TTM) $9.80

Buy IsoPlexis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy IsoPlexis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

IsoPlexis price performance over time

Historical closes compared with the close of $1.75 from 2022-09-23

1 week (2022-09-19) -7.89%
1 month (2022-08-26) -3.31%
3 months (2022-06-24) -22.22%
6 months (2022-03-25) -51.92%
1 year (2021-09-22) N/A
2 years (2020-09-22) N/A
3 years (2019-09-22) N/A
5 years (2017-09-22) N/A

Is IsoPlexis stock undervalued or overvalued?

Valuing IsoPlexis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IsoPlexis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

IsoPlexis's P/E ratio

IsoPlexis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, IsoPlexis shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, IsoPlexis's P/E ratio is best considered in relation to those of others within the medical devices industry or those of similar companies.

    IsoPlexis financials

    Revenue TTM $18.7 million
    Gross profit TTM $8.8 million
    Return on assets TTM -42.88%
    Return on equity TTM -126.91%
    Profit margin 0%
    Book value $2.32
    Market capitalisation $69 million

    TTM: trailing 12 months

    IsoPlexis share dividends

    We're not expecting IsoPlexis to pay a dividend over the next 12 months.

    IsoPlexis overview

    IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut. .

    Frequently asked questions

    What percentage of IsoPlexis is owned by insiders or institutions?
    Currently 11.183% of IsoPlexis shares are held by insiders and 75.162% by institutions.
    How many people work for IsoPlexis?
    Latest data suggests 459 work at IsoPlexis.
    When does the fiscal year end for IsoPlexis?
    IsoPlexis's fiscal year ends in December.
    Where is IsoPlexis based?
    IsoPlexis's address is: 35 NE Industrial Road, Branford, CT, United States, 06405
    What is IsoPlexis's ISIN number?
    IsoPlexis's international securities identification number is: US4650051067

    More guides on Finder

    Ask an Expert

    You are about to post a question on

    • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
    • is a financial comparison and information service, not a bank or product provider
    • We cannot provide you with personal advice or recommendations
    • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

    By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

    Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
    Go to site